KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the European Patent Office has granted European Patent EP2376101B1, “Beta-Arrestin Effectors and Compositions and Methods of Use Thereof,” which covers the composition of matter for TRV027 and uses thereof. The patent is expected to provide coverage for TRV027 in the European Union until at least 2029. Corresponding patents have previously issued in the U.S. and other markets, and further patent applications are pending throughout the world. TRV027 is an investigational peptide drug currently being studied in the BLAST-AHF Phase 2b trial for the treatment of acute heart failure (AHF).
“This EU patent bolsters our intellectual property estate, providing significant coverage of TRV027 and its use in the treatment of acute heart failure in one of the world’s largest markets,” stated Maxine Gowen, Ph.D., chief executive officer. “Together with our previously granted patents in the United States and elsewhere, we believe we are building a comprehensive and enforceable worldwide patent estate to protect the commercial potential of TRV027.”
Trevena owns all rights to the TRV027 patent portfolio, which includes issued U.S. composition of matter and method of use patents for TRV027 that extends until at least 2031, as well as issued patents in Australia, New Zealand, China, and Japan. Additional patent applications are pending in certain other major countries worldwide. Trevena has granted Allergan plc an exclusive, worldwide option to license TRV027 that may be exercised up to a specified time period after Trevena delivers to Allergan the data from the BLAST-AHF Phase 2b clinical trial.
TRV027 targets the angiotensin II type 1 receptor, a key driver of AHF, with an innovative “biased ligand” mechanism which protects the heart, kidneys and vasculature. This profile has the potential to become an important new therapy for AHF patients.
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified – TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (completed Phase 2), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for acute migraine and other CNS disorders (preclinical).
Cautionary Note on Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development of its therapeutic candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to the Company’s intellectual property, including the strength, extent of coverage and enforceability of the TRV027 patent portfolio and whether pending patents related to TRV027 will issue; the status, timing, costs, results and interpretation of the Company’s clinical trials; the uncertainties inherent in conducting clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials; expectations for regulatory approvals; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates, including whether Actavis will exercise its exclusive option to license TRV027; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.